Literature DB >> 25888631

Deregulation of dicer and mir-155 expression in liposarcoma.

Bruno Vincenzi1, Michele Iuliani2, Alice Zoccoli2, Francesco Pantano1, Marco Fioramonti2, Delia De Lisi1, Anna Maria Frezza1, Carla Rabitti3, Giuseppe Perrone3, Andrea Onetti Muda3, Antonio Russo4, Antonio Giordano5,6, Daniele Santini1, Angelo Paolo Dei Tos7, Giuseppe Tonini1.   

Abstract

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versus normal fat. The tumor samples from LPS patients showed a significantly lower Dicer expression versus normal adipose tissue, while Drosha levels did not differ. Concerning mir155 expression levels, our results demonstrated a significant mir-155 up-regulation in all LPS subtypes versus normal adipose tissue except for WDLS. These findings demonstrate for the first time that Dicer is deregulated in LPS and show that mir-155 is differentially expressed in LPS subgroups and it could be a promising tool to improve LPS disease stratification and differential diagnosis.

Entities:  

Keywords:  Dicer; Drosha; liposarcoma; mir-155

Mesh:

Substances:

Year:  2015        PMID: 25888631      PMCID: PMC4496377          DOI: 10.18632/oncotarget.3201

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  24 in total

1.  MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Authors:  Matthieu Bui Nguyen Binh; Xavier Sastre-Garau; Louis Guillou; Gonzague de Pinieux; Philippe Terrier; Réal Lagacé; Alain Aurias; Isabelle Hostein; Jean Michel Coindre
Journal:  Am J Surg Pathol       Date:  2005-10       Impact factor: 6.394

2.  RNASEN regulates cell proliferation and affects survival in esophageal cancer patients.

Authors:  Nobuyoshi Sugito; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Hiroki Kurehara; Takuya Ando; Ryota Mori; Nobuhiro Takashima; Ryo Ogawa; Yoshitaka Fujii
Journal:  Clin Cancer Res       Date:  2006-11-22       Impact factor: 12.531

3.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

4.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

5.  Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.

Authors:  Samuel Singer; Nicholas D Socci; Grazia Ambrosini; Elliot Sambol; Penelope Decarolis; Yuhsin Wu; Rachael O'Connor; Robert Maki; Agnes Viale; Chris Sander; Gary K Schwartz; Cristina R Antonescu
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

6.  Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients.

Authors:  Richard J Flavin; Paul C Smyth; Stephen P Finn; Alexandros Laios; Sharon A O'Toole; Ciara Barrett; Martina Ring; Karen M Denning; Jinghuan Li; Sinead T Aherne; Natasha A Aziz; Araibi Alhadi; Brian L Sheppard; Massimo Loda; Cara Martin; Orla M Sheils; John J O'Leary
Journal:  Mod Pathol       Date:  2008-03-07       Impact factor: 7.842

7.  Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization.

Authors:  Matt J Neville; Jenny M Collins; Anna L Gloyn; Mark I McCarthy; Fredrik Karpe
Journal:  Obesity (Silver Spring)       Date:  2010-10-14       Impact factor: 5.002

8.  Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.

Authors:  Konstantin J Dedes; Rachael Natrajan; Maryou B Lambros; Felipe C Geyer; Maria Angeles Lopez-Garcia; Kay Savage; Robin L Jones; Jorge S Reis-Filho
Journal:  Eur J Cancer       Date:  2010-09-09       Impact factor: 9.162

9.  Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.

Authors:  G Grelier; N Voirin; A-S Ay; D G Cox; S Chabaud; I Treilleux; S Léon-Goddard; R Rimokh; I Mikaelian; C Venoux; A Puisieux; C Lasset; C Moyret-Lalle
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

Review 10.  MicroRNA: implications for cancer.

Authors:  Stefanie Sassen; Eric A Miska; Carlos Caldas
Journal:  Virchows Arch       Date:  2007-11-27       Impact factor: 4.064

View more
  9 in total

1.  Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.

Authors:  Lucia Casadei; Federica Calore; Chad J Creighton; Michele Guescini; Kara Batte; O Hans Iwenofu; Abeba Zewdu; Danielle A Braggio; Kate Lynn Bill; Paolo Fadda; Francesca Lovat; Gonzalo Lopez; Pierluigi Gasparini; James L Chen; Raleigh D Kladney; Gustavo Leone; Dina Lev; Carlo M Croce; Raphael E Pollock
Journal:  Cancer Res       Date:  2017-06-06       Impact factor: 12.701

Review 2.  Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Authors:  Jun Lu; David Wood; Evan Ingley; Sulev Koks; Daniel Wong
Journal:  Mol Biol Rep       Date:  2021-04-24       Impact factor: 2.316

3.  Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.

Authors:  Aleksandar Boro; David Bauer; Walter Born; Bruno Fuchs
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

4.  Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.

Authors:  Nikolaos Kapodistrias; Konstantinos Mavridis; Anna Batistatou; Penelope Gogou; Vasilios Karavasilis; Ioannis Sainis; Evangelos Briasoulis; Andreas Scorilas
Journal:  Oncotarget       Date:  2017-01-24

5.  miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling.

Authors:  Ying Z Mazzu; Yulan Hu; Yawei Shen; Thomas Tuschl; Samuel Singer
Journal:  Sci Rep       Date:  2019-03-01       Impact factor: 4.379

Review 6.  MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression.

Authors:  Merav Kedmi; Aldema Sas-Chen; Yosef Yarden
Journal:  J Clin Med       Date:  2015-08-13       Impact factor: 4.241

7.  MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma.

Authors:  Melissa Vos; Ruben Boers; Anne L M Vriends; Joachim Boers; Patricia F van Kuijk; Winan J van Houdt; Geert J L H van Leenders; Michal Wagrodzki; Wilfred F J van IJcken; Joost Gribnau; Dirk J Grünhagen; Cornelis Verhoef; Stefan Sleijfer; Erik A C Wiemer
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

Review 8.  Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.

Authors:  Lingge Yang; Shiqi Chen; Peng Luo; Wangjun Yan; Chunmeng Wang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 9.  Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma.

Authors:  Lucia Casadei; Fernanda Costas Casal de Faria; Alexandra Lopez-Aguiar; Raphael E Pollock; Valerie Grignol
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.